Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 22;13(1):41.
doi: 10.1038/s41408-023-00804-y.

Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

Noopur Raje  1 , María-Victoria Mateos  2 , Shinsuke Iida  3 , Donna Reece  4
Affiliations
Review

Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

Noopur Raje et al. Blood Cancer J. .

Erratum in

Abstract

Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available treatments and will require additional therapy. However, data are still lacking on how best to sequence regimens in the relapsed/refractory (RR) setting after the failure of early-line lenalidomide, bortezomib, and/or daratumumab, the most commonly used agents in clinical practice today. With the treatment landscape rapidly changing in response to emerging clinical trial data and approvals of several new drugs and additional combinations, it is critically important to focus on patients with RRMM. Variability in patient baseline characteristics, such as the number of prior lines of treatment, refractoriness to prior treatments, prior stem cell transplant, and timing and dosing of prior lenalidomide, makes it difficult to select the best options for patients with RRMM for whom first-line treatments have failed. The aim of this review is to provide both an overview of current therapies and future directions within the RRMM treatment landscape, and a framework for clinicians to choose the most promising next treatment option.

PubMed Disclaimer

Conflict of interest statement

NR reports consulting for Amgen, Bristol Myers Squibb, Janssen, Sanofi, Takeda, AstraZeneca, and C4 Therapeutics, and serving on the advisory boards of Caribou and Immuneel, and research funding from bluebird bio; M-VM reports payment or honoraria from Janssen, Bristol Myers Squibb, Amgen, Takeda, GlaxoSmithKline, Sanofi, Regeneron, Pfizer, and Seagen; SL reports receiving support for the present manuscript from Bristol Myers Squibb, and grant or contract support from Bristol Myers Squibb, Janssen, Sanofi, Pfizer, AbbVie, Daiichi Sankyo, Takeda, Ono, Chugai, Amgen, GlaxoSmithKline, and Kyowa Kirin, and payments or honoraria from Bristol Myers Squibb, Janssen, Takeda, Ono, Pfizer, Sanofi, and Celgene; DR reports consulting fees from Janssen, Bristol Myers Squibb, Amgen, and Takeda, and payment or honoraria from Janssen, Bristol Myers Squibb, Amgen, Takeda, and Merck, and research funding from Janssen, Bristol Myers Squibb, Amgen, Otsuka, Merck, and Takeda, and serving on the board of directors or advisory committees for Janssen and Bristol Myers Squibb.

Figures

Fig. 1
Fig. 1. Overview of current treatment options and future directions in the early RRMM treatment landscape.
The agents commonly used for treatment of patients with multiple myeloma in frontline and early relapsed/refractory settings are presented on the left (Current Treatments); agents being evaluated in clinical trials or entering the treatment space are described on the right (Future Directions). ADC antibody-drug conjugate, BCMA B-cell maturation antigen, CAR chimeric antigen receptor, CELMoD cereblon E3 ligase modulating drug, FcRH5 Fc receptor-homolog 5, GPRC5D G-protein coupled receptor family C group 5, mAb monoclonal antibody, MM multiple myeloma, RRMM relapsed/refractory multiple myeloma, SLAMF7 SLAM family member 7.
See this image and copyright information in PMC

References

    1. Caraccio C, Krishna S, Phillips DJ, Schurch CM. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Front Immunol. 2020;11:501. doi: 10.3389/fimmu.2020.00501. - DOI - PMC - PubMed
    1. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94. doi: 10.1038/s41408-020-00359-2. - DOI - PMC - PubMed
    1. Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9:167. doi: 10.3390/cells9010167. - DOI - PMC - PubMed
    1. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–19. doi: 10.1016/j.mayocp.2015.11.007. - DOI - PMC - PubMed
    1. Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252–64. doi: 10.1111/bjh.14213. - DOI - PMC - PubMed

Publication types

MeSH terms